RE:RE:RE:RE:How do we determine fair market cap from a licensing deal?
In this hypothetical scenario its BYOC, bring your own cells. The cell pouch is a universal platform, although they are testing T1D, hemophillia and hypothyroid treatments, I don't see large pharma being too interested in sernovas cells, but rather the platform. The clinical/preclinical trials prove the effectiveness of the cell pouch in ensuring cell survival and treatment deliverability. I don't think there is anything proprietary about the cells Sernova is using, so I don't see why Sernova would include them in any sort of deal.
The only caveat would be if the FDA would need a clinical trial for each combination of cell and pouch. That would suck, but if the FDA approved the cell pouch in general, and then other pharmas get their stem cell treatments approved independently, then wouldnt they be allowed to stick their approved cells into the approved pouch with no need for trials?
If that is a concern, then Sernova should be focusing on developing the pouch as a one size fits all where the protocol is the exact same regardless of which cells are being used. Sernova would have to develop a means of informing clients of the expected oxygen levels within the pouch and expected levels of vascularization. That way pharma could determine the amount of their cells needed to ensure efficacy. I think Sernova's trials serve only as an example of what other pharmas could do